Dare Bioscience, Inc. — Form 8-K
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Dare Bioscience (market cap ~$21.3M) completed an offering dated August 14, 2026, issuing 4,085,687 common shares and 293,894 pre-funded warrants to unnamed purchasers for aggregate ~$6M. Company also issued Series A warrants (5-year, $1.37 exercise price) and Series B warrants (2-year, $1.37 exercise price) in 1:1 ratio to shares/pre-funded warrant shares. All securities registered on Form S-3; pre-funded warrants exercisable immediately at $0.0001/share. Placement agent: Ladenburg Thalmann Co.
Why this rating
Routine financing ~28% of market cap. Dilutive but standard capital raise for micro-cap biotech. No transformational terms disclosed.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.